Real-World Experience with Rhopressa® (netarsudil ophthalmic solution) 0.02%
Glaucoma experts answer Frequently Asked Questions about the therapeutic role of the first FDA-approved Rho kinase (ROCK) inhibitor
These videos reflect the views and experiences of the participating physicians.
They have been compensated for their time by Aerie Pharmaceuticals.
Nathan M. Radcliffe, MD New York Eye Surgery Center, Bronx, NY; Asst. Professor of Ophthalmology at Mt. Sinai School of Medicine, New York, NY
Dr. Radcliffe is a consultant to Equinox, Alcon Laboratories, Allergan, Glaukos, Bausch + Lomb, Aerie Pharmaceuticals, Novartis, Sight Sciences, Ocular Science, Reichert, Iridex, Lumenis, New World Medical, Beaver Visitec, and Carl Zeiss Meditec.
Steven T. Simmons, MD Glaucoma Consultants of the Capital Region; Assoc. Clinical Professor of Ophthalmology at Albany Medical College, NY
Dr. Simmons is a consultant to Allergan and Aerie, has conducted research for Innfocus, Allergan, and Zeiss, and is a speaker for B+L.
Inder Paul Singh, MD The Eye Centers of Racine and Kenosha, WI
Dr. Singh is a speaker, consultant and has conducted research for Aerie, Allergan, Alcon, Glaukos, Ivantis, B+L, Shire, Ellex, Zeiss, New World Medical. He is also a consultant for Kala, Eyepoint and imprimis.
IMPORTANT SAFETY INFORMATION
Dosage and Administration: Twice a day dosing is not well tolerated and is not recommended. If RHOPRESSA® is to be used concomitantly with other topical ophthalmic drug products to lower IOP, administer each drug product at least 5 minutes apart.
Warnings and Precautions:
Bacterial Keratitis - There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.
Adverse reactions: The most common ocular adverse reaction observed in controlled clinical studies with RHOPRESSA® dosed once daily was conjunctival hyperemia which was reported in 53% of patients. Other common (approximately 20%) adverse reactions were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients.
The corneal verticillata seen in RHOPRESSA®-treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes in patients. Most corneal verticillata resolved upon discontinuation of treatment.
RHOPRESSA® (netarsudil ophthalmic solution) 0.02% is a Rho kinase inhibitor indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Dosage and Administration: The recommended dosage is one drop in the affected eye(s) once daily in the evening.
For more information about RHOPRESSA®, including Full Prescribing Information, please visit www.rhopressa.com.